Erratum: Author's Affiliation Correction. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (World J Clin Cases 2019; Aug 6; 7 (15): 1964-1977).

[This corrects the article on p. 1964 in vol. 7, PMID: 31423428.]. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This manuscript is an author's affiliation correction for type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (World J Clin Cases 2019; Aug 6; 7 (15): 1964-1977).

CORRECTION

Correction to: Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor-positive gastric cancer. World J Clin Cases 2019; 7(15): 1964-1977 [PMID: 31423428 DOI: 10.12998/wjcc.v7.i15.1964].

In this article[1], one of the affiliation of the first author was lacked. Akio Kaito, the first author, belonged to Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo 163-8001, Japan. We apologize for the error.